Calendario de promoción Regulus Therapeutics Inc.
Horario avanzado
gráfico sencillo
Acerca de la empresa Regulus Therapeutics Inc.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. más detalles| IPO date | 2012-10-04 |
|---|---|
| ISIN | US75915K3095 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.regulusrx.com |
| Цена ао | 1.29 |
| Cambio de precio por día: | +15.33% (1.5) |
|---|---|
| Cambio de precio por semana.: | +26.28% (1.37) |
| Cambio de precio por mes: | +27.21% (1.36) |
| Cambio de precio en 3 meses.: | +12.34% (1.54) |
| Cambio de precio en seis meses: | +10.19% (1.57) |
| Cambio de precio por año: | -39.93% (2.88) |
| Cambio de precio en 3 años.: | +499.45% (0.2886) |
| Cambio de precio en 5 años.: | +135.41% (0.7349) |
| Cambio de precio desde principios de año.: | +9.49% (1.58) |
|
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
|||||||||||||||||||||||||||||||||||||
| Instituciones | Volumen | Compartir, % |
|---|---|---|
| Federated Hermes, Inc. | 3875578 | 5.92 |
| FMR, LLC | 2922600 | 4.46 |
| NEA Management Company, LLC | 1945579 | 2.97 |
| DAFNA Capital Management, LLC | 1111049 | 1.7 |
| Vanguard Group Inc | 286431 | 0.44 |
| Victory Capital Management Inc. | 271736 | 0.42 |
| Sarissa Capital Management, LP | 185183 | 0.28 |
| Exome Asset Management LLC | 178404 | 0.27 |
| Geode Capital Management, LLC | 122521 | 0.19 |
| Renaissance Technologies, LLC | 54600 | 0.08 |
| ETF | Compartir, % | Rentabilidad del año, % | Dividendos, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.02905 | 17.09 | 1.54048 |
| Avantis U.S Small Cap Equity ETF | 0.00491 | 27.77 | 1.68271 |
ProShares UltraPro Russell2000
|
0.00248 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.00063 | 5.92 | 1.47892 |
| Vanguard Russell 2000 ETF | 0 | 17.16 | 1.48801 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| Vanguard Russell 2000 Growth ETF | 0 | 23.05 | 0.60264 |
| 0 | 30.38 | 1.39 |
| Supervisor | Título profesional | Pago | año de nacimiento |
|---|---|---|---|
| Mr. Joseph P. Hagan M.B.A. | CEO & Director | 958.23k | 1969 (56 años) |
| Ms. Crispina Calsada CPA | Chief Financial Officer | 579.3k | 1970 (55 años) |
| Mr. Christopher Ray Aker J.D. | Senior VP, General Counsel & Corporate Secretary | 575.94k | 1961 (64 año) |
| Mr. Daniel J. Penksa | VP of Finance & Controller | N/A | 1986 (39 años) |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations | N/A | |
| Dr. Rekha Garg M.D., M.S. | Chief Medical Officer | N/A | |
| Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research & Development and Director | N/A | 1969 (56 años) |
| Mr. Edmund Lee Ph.D. | Vice President of Translational Medicine | N/A |
DIRECCIÓN: United States, San Diego. CA, 4224 Campus Point Court - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.regulusrx.com
Sitio web: https://www.regulusrx.com
